Cote d'Ivoire vs Kazakhstan: The number of people with susceptibility test result for rifampicin
Cote d'Ivoire
8,494
in 2021
Kazakhstan
5,121
in 2021
Cote d'Ivoire rank
25th
Kazakhstan rank
28th
The number of people with susceptibility test result for rifampicin over time
- Cote d'Ivoire
- Kazakhstan
How they compare
Cote d'Ivoire currently reports 8,494 against 5,121 in Kazakhstan, a difference of 3,373.
That makes Cote d'Ivoire's figure about 1.7 times Kazakhstan's.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Kazakhstan ahead.
Cote d'Ivoire ranks 25th and Kazakhstan ranks 28th of 155 countries.
Kazakhstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Kazakhstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,175 | 5,272 | 2,097 | Kazakhstan |
| 2020s | 4,890 | 4,990 | 100 | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Cote d'Ivoire or Kazakhstan?
- Cote d'Ivoire, at 8,494 against 5,121 in Kazakhstan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Cote d'Ivoire and Kazakhstan?
- 3,373, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cote d'Ivoire and Kazakhstan?
- 5 years are reported by both, from 2017 to 2021.
- How do Cote d'Ivoire and Kazakhstan rank globally for the number of people with susceptibility test result for rifampicin?
- Cote d'Ivoire ranks 25th and Kazakhstan ranks 28th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.